Comparison of intravitreal ranibizumab and aflibercept for the treatment of diabetic macular edema: a real-world study.

In a real-world setting, ranibizumab and aflibercept were both found to be effective in the first-line treatment of DME. Patients with DME who received fewer injections in the real-world could achieve visual and anatomical results comparable to randomized controlled trials participants.